ECM
AXDX

ExodusPoint Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

ExodusPoint Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4,000
Closed -$743K – 1521
2019
Q3 		$743K Buy
+4,000
New +$773K 0.03% 490

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

ExodusPoint Capital Management's AXDX Position: Q3 2021 in Review

ExodusPoint Capital Management sold out of Accelerate Diagnostics (AXDX) in Q3 2021, closing a stake of 3,278 shares — an estimated $264K sold.

ExodusPoint Capital Management first reported a position in AXDX in Q3 2020 and held it in 3 quarters. The position peaked at $264K in Q2 2021. 105 funds tracked by Wall St. Rank hold AXDX as of Q3 2021.

  • ExodusPoint Capital Management reported no remaining Accelerate Diagnostics position as of Q3 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 3,278 Accelerate Diagnostics shares in Q3 2021, an estimated $264K.
  • ExodusPoint Capital Management first reported a position in Accelerate Diagnostics in Q3 2020 and held it in 3 quarters.
  • ExodusPoint Capital Management's Accelerate Diagnostics position peaked at $264K in Q2 2021.
  • 105 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.